FDA Approves Dupixent for Chronic Spontaneous Urticaria

Follow Drugslib on

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

WEDNESDAY, April 23, 2025 -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria.

The approval is for patients 12 years and older who remain symptomatic despite histamine-1 antihistamine treatment.

The approval is based on data from two phase 3 clinical studies, which included biologic-naïve patients who were symptomatic despite the use of antihistamines. Dupixent was assessed as an add-on therapy to standard-of-care antihistamines versus antihistamines alone. In both studies, Dupixent met the primary and key secondary end points, showing reductions in itch severity and urticaria activity at 24 weeks. Dupixent increased the likelihood of well-controlled disease or complete response at 24 weeks versus placebo. Safety results were generally consistent with the known safety profile of Dupixent for approved indications.

"Chronic spontaneous urticaria patients with uncontrolled disease experience highly burdensome itch and hives that can significantly disrupt daily living," Alyssa Johnsen, M.D., Ph.D., the global therapeutic area head for immunology and oncology development at Sanofi, said in a statement. "This FDA approval provides a new treatment option to help address the underlying drivers of these severe and recurring signs and symptoms."

This approval of Dupixent was granted to Sanofi.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-04-24 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords